Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial
- PMID: 23832433
- DOI: 10.1002/ptr.5025
Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial
Erratum in
-
Correction to "Efficacy and safety of curcumin in major depressive disorder: A randomized controlled trial".Phytother Res. 2024 May;38(5):2594. doi: 10.1002/ptr.8142. Epub 2024 Mar 20. Phytother Res. 2024. PMID: 38507274 No abstract available.
Abstract
Curcumin, an active ingredient of Curcuma longa Linn (Zingiberaceae), has shown potential antidepressant-like activity in animal studies. The objectives of this trial were to compare the efficacy and safety of curcumin with fluoxetine in patients with major depressive disorder (MDD). Herein, 60 patients diagnosed with MDD were randomized in a 1:1:1 ratio for six weeks observer-masked treatment with fluoxetine (20 mg) and curcumin (1000 mg) individually or their combination. The primary efficacy variable was response rates according to Hamilton Depression Rating Scale, 17-item version (HAM-D17 ). The secondary efficacy variable was the mean change in HAM-D17 score after six weeks. We observed that curcumin was well tolerated by all the patients. The proportion of responders as measured by the HAM-D17 scale was higher in the combination group (77.8%) than in the fluoxetine (64.7%) and the curcumin (62.5%) groups; however, these data were not statistically significant (P = 0.58). Interestingly, the mean change in HAM-D17 score at the end of six weeks was comparable in all three groups (P = 0.77). This study provides first clinical evidence that curcumin may be used as an effective and safe modality for treatment in patients with MDD without concurrent suicidal ideation or other psychotic disorders. .
Keywords: CNS; antidepressant; clinical trial simulations; curcumin; major depressive disorder.
Copyright © 2013 John Wiley & Sons, Ltd.
Similar articles
-
Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.Int Clin Psychopharmacol. 2010 Nov;25(6):305-14. doi: 10.1097/YIC.0b013e32833a86aa. Int Clin Psychopharmacol. 2010. PMID: 20856123 Clinical Trial.
-
Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.Asian J Psychiatr. 2014 Apr;8:26-32. doi: 10.1016/j.ajp.2013.09.009. Epub 2013 Sep 30. Asian J Psychiatr. 2014. PMID: 24655622 Clinical Trial.
-
Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.J Clin Psychopharmacol. 2018 Jun;38(3):226-233. doi: 10.1097/JCP.0000000000000878. J Clin Psychopharmacol. 2018. PMID: 29620692 Clinical Trial.
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
-
Venlafaxine extended-release: a review of its use in the management of major depression.CNS Drugs. 2001;15(8):643-69. doi: 10.2165/00023210-200115080-00007. CNS Drugs. 2001. PMID: 11524036 Review.
Cited by
-
Curcumin as a Multifunctional Spice Ingredient against Mental Disorders in Humans: Current Clinical Studies and Bioavailability Concerns.Life (Basel). 2024 Apr 5;14(4):479. doi: 10.3390/life14040479. Life (Basel). 2024. PMID: 38672750 Free PMC article. Review.
-
Cool the Inflamed Brain: A Novel Anti-inflammatory Strategy for the Treatment of Major Depressive Disorder.Curr Neuropharmacol. 2024;22(5):810-842. doi: 10.2174/1570159X21666230809112028. Curr Neuropharmacol. 2024. PMID: 37559243 Free PMC article. Review.
-
Neurotrophic basis to the pathogenesis of depression and phytotherapy.Front Pharmacol. 2023 Apr 6;14:1182666. doi: 10.3389/fphar.2023.1182666. eCollection 2023. Front Pharmacol. 2023. PMID: 37089920 Free PMC article. Review.
-
Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials.ACS Pharmacol Transl Sci. 2023 Mar 6;6(4):447-518. doi: 10.1021/acsptsci.2c00012. eCollection 2023 Apr 14. ACS Pharmacol Transl Sci. 2023. PMID: 37082752 Free PMC article. Review.
-
Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials.Int J Mol Sci. 2023 Feb 24;24(5):4476. doi: 10.3390/ijms24054476. Int J Mol Sci. 2023. PMID: 36901908 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical